EUVIMEDEUVIMED entdecken
Crossref

Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

Doris T Tang iD, Zhimin Du, Kin S Yang, Brian P Bestvater, Joshua Kaplan, Megan E Neubig, Casey L Olen iD, Bart Phillips, Peiyuan Wang, Thomas Hudson iD, Bruno Marchand, Julie Chan und 17 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Doris T Tang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States. Hauptthemen laut MEDLINE: Receptors, Lysophosphatidic Acid, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We describe the discovery and preclinical characterization of a potent and selective lysophosphatidic acid receptor 1 (LPAR1) antagonist with a direct-acting antifibrotic mechanism. 18a was initially identified as a potent non-carboxylic acid LPAR1 antagonist in an LPA-induced myocardin-related transcription factor A (MRTF-A) nuclear translocation assay. Modifications to the aromatic elements in the structure allowed for improvements in metabolic stability and the mitigation of GSH adduct formation, but in vitro to in vivo clearance disconnects were observed with several potent sulfonamides (e.g., 27b) across preclinical species. Through modification of the sulfonamide, 42 (GS-2278) emerged as a potent LPAR1 antagonist with a suitable in vitro profile and desirable pharmacokinetic properties for oral QD dosing. GS-2278 dose-dependently blocked LPA-induced histamine release and demonstrated efficacy in an interventional model of bleomycin-induced lung fibrosis. However, CNS-related toxicity was observed in dogs, and based on these findings, the clinical development of GS-2278 for IPF was halted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Lysophosphatidic AcidIdiopathic Pulmonary FibrosisAnimalsDogsHumansSulfonamidesMiceMaleRatsStructure-Activity RelationshipDrug DiscoveryBleomycin

Substanzen

Receptors, Lysophosphatidic AcidSulfonamidesLPAR1 protein, humanBleomycin

Autor:innen und Institutionen

  • Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States.

ORCID-Profile: Doris T Tang, Casey L Olen, Thomas Hudson, Anna Zagorska, Julie Farand

Zitieren

APA

Tang, D. T., Du, Z., Yang, K. S., Bestvater, B. P., Kaplan, J., Neubig, M. E., Olen, C. L., Phillips, B., Wang, P., Hudson, T., Marchand, B., Chan, J., Sharma, M., Hu, Y., Matles, M., Nejati, E., Chojnacka, M., Adams, C., Pong, C., …, & Farand, J. (2025). Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02090

Vancouver

Tang DT, Du Z, Yang KS, Bestvater BP, Kaplan J, Neubig ME, et al. Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02090

BibTeX
@article{Tang2025,
  author = {Tang, Doris T and Du, Zhimin and Yang, Kin S and Bestvater, Brian P and Kaplan, Joshua and Neubig, Megan E and Olen, Casey L and Phillips, Bart and Wang, Peiyuan and Hudson, Thomas and Marchand, Bruno and Chan, Julie and Sharma, Monika and Hu, Yiding and Matles, Mike and Nejati, Elham and Chojnacka, Maja and Adams, Clifton and Pong, Cassie and Holsapple, Kevin and Budas, Grant and Tsui, Vickie and Venkataramani, Chandrasekar and Lazerwith, Scott E and Notte, Gregory T and Watkins, William J and McGlinchey, Ellen and Zagorska, Anna and Farand, Julie},
  title = {Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02090}
}
Kostenlos starten →